Because Cufanchu Powder Veterinary Grade API is supplied as a micronized powder with multi-dosage compatibility, downstream formulation decisions are determined by particle size distribution, bulk density, moisture sensitivity, and the intended route of administration. The material is released under a certificate of analysis stating assay on dried substance, loss on drying, residue on ignition, residual solvent profile, and heavy metals content in accordance with VICH GL18, current pharmacopoeial general monographs, and Good Manufacturing Practice provisions. In the downstream applications that follow, the powder is treated as a pharmacologically active component, not as a feed additive carrier, except in the medicated premix scenario where national veterinary feed law applies in parallel with pharmaceutical GMP. Cleanroom classification, equipment wetting, blending sequence, and containment strategy are adjusted according to the dusting tendency of the powder and the homogeneity requirement of the final dose unit. Because processing behavior changes when the active substance is exposed to moisture, shear, and heat, each application path specifies handling limits that have been observed to cause batch rejection or rework on production-scale equipment.

Direct Compression Failure Modes When API Median Particle Size Falls Below 75 µm

Tablet manufacture with Cufanchu Powder is constrained by the API’s particle size distribution and compactibility. If the median particle size D50 falls below 75 µm and storage relative humidity exceeds 60%, the powder requires pre-drying in a forced-air oven at 40–45°C for 4 h or until loss-on-drying is ≤1.0%. In a direct compression formula for a 25 mg tablet with a 250 mg core weight, the API fraction is 10.0% w/w. The excipient system consists of microcrystalline cellulose PH-102 77.5% w/w, crospovidone XL-10 5.0% w/w, colloidal silicon dioxide 1.0% w/w, and sodium stearyl fumarate 1.5% w/w. When the label claim is increased to 50 mg per 300 mg core, the API fraction is 16.7% w/w and the microcrystalline cellulose fraction is reduced accordingly. The downstream process screens the API through a 500 µm perforated sieve, blends it in a 500 L V-shell blender at 60% fill and 25 rpm for 20 min, and compresses it on a rotary tablet press with D-tooling at 5–15 kN compaction force. Tablet hardness is held at 60–100 N; friability is controlled at ≤1.0% by USP Chapter 1216; disintegration is controlled at ≤15 min by Ph. Eur. 2.9.1. Observed production-scale failure modes include stratification of fine API fractions in V-shell blenders when fill exceeds 65% and rotation speed is maintained above 25 rpm; dense excipients settle while micronized API migrates upward, producing active content variation above 6.0% RSD across the blend. Reducing fill to 60% and pre-blending API with 10% of the microcrystalline cellulose for 5 min before full dilution lowers blend RSD to ≤3.0%. If the direct compression blend shows insufficient flow because the API fraction has a compressibility index above 25 by USP Chapter 616, dry granulation is introduced. The blend is compacted on a roller compactor with a gap of 1.5–2.0 mm, milled through a 1.25 mm screen, and recompressed. Compliance anchors include Ph. Eur. 2.9.5 for uniformity of mass, Ph. Eur. 2.9.40 for uniformity of dosage units, USP Chapter 905 with an acceptance value ≤15.0, 21 CFR Part 210 and 211, and VICH GL18 residual solvent limits. Finished dose types include 10 mg, 25 mg, and 50 mg uncoated or film-coated tablets for oral administration to companion animals.

Manufacture of a parenteral solution from Cufanchu Powder shifts the critical control point from powder flow to depyrogenation, subvisible particulate burden, and pH-dependent solubility. A 10.0% w/v injectable solution, equivalent to 100 mg/mL, is prepared by dissolving 10.0 kg API in 80 L Water for Injection at 25–30°C. The batch is then supplemented with sodium chloride 0.65% w/v for isotonicity and benzyl alcohol 1.5% v/v as a preservative only where multidose vials are permitted and residue depletion data support use in the target species; for food-producing species, single-dose unpreserved vials are the default configuration unless residue data indicate otherwise. The volume is made to 100 L with Water for Injection, and pH is adjusted to 4.5–6.5 with 0.1 N hydrochloric acid or sodium hydroxide. The solution is clarified through a 0.45 µm polyethersulfone prefilter and then sterilized through a 0.22 µm PVDF membrane under nitrogen pressure of 0.5–1.0 bar. If terminal sterilization at 121°C for 15 min is supported by stability data, the filled vials are processed in a steam autoclave with an F0 value not less than 12 min; otherwise, aseptic filling occurs in a Restricted Access Barrier System after sterilizing filtration. In production-scale campaigns, a top-entry agitator can introduce air entrapment that raises subvisible particulate counts above USP Chapter 788 limits; a bottom-mounted magnetic stirrer or recirculation loop with a low-shear impeller is therefore preferred for the compounding vessel. Glass vials are depyrogenated in a tunnel at 250°C for 30 min; elastomeric stoppers are washed, siliconized, and steam-sterilized at 121°C for 30 min. Dissolved oxygen is maintained below 1.0 mg/L by nitrogen overlay during compounding. Compliance anchors include USP Chapter 71 for sterility, Ph. Eur. 2.6.14 for bacterial endotoxins with a limit of ≤0.5 EU/mg where the injectable route requires pyrogen control, USP Chapter 788 for subvisible particulate matter, 21 CFR Part 210 and 211, Ph. Eur. 5.1.1 for methods of preparation of sterile products, VICH GL18 for residual solvents, and ASTM F1929-24 for package integrity by dye penetration. Finished product types include 10 mL, 50 mL, 100 mL amber Type I glass vials and 250 mL polypropylene bottles for intravenous or subcutaneous administration in cattle and swine.

Why Does Low-Dose Capsule Filling Avoid Wet Massing for Cufanchu API?

Oral capsule formulations containing Cufanchu API are selected for species requiring dose titration and for animals that reject tablet administration. In a size 3 hard gelatin capsule with a fill weight of 150 mg, an API content of 25 mg corresponds to 16.7% w/w. The excipient system is pregelatinised starch 82.8% w/w and talc 0.5% w/w. No magnesium stearate is used above 0.5% w/w because hydrophobic lubricant films can reduce dissolution rate in low-dose capsules. Blending is performed in a 300 L bin blender at 20 rpm for 15 min. The blend is then filled on a Bosch GKF 1500 or equivalent capsule filler at 150,000 capsules/h where the target dose and hopper configuration permit. Weight sorting rejects capsules outside ±3.0% of target fill weight, and in-line metal detection is set to 1.5 mm ferrous and 2.0 mm non-ferrous sensitivity. Compliance anchors include Ph. Eur. 2.9.40 for uniformity of dosage units, USP Chapter 905 with acceptance value ≤15.0, USP Chapter 701 and Ph. Eur. 2.9.1 for disintegration, 21 CFR Part 211, and VICH GL18 for residual solvents. Finished dosage types include 5 mg, 10 mg, and 25 mg capsules in PVC/PVDC/aluminum blister packs for companion animals.

A 20.0% w/w water-soluble oral powder for poultry drinking-water medication is prepared by blending 200 g/kg API with spray-dried lactose monohydrate q.s. to 1 kg, povidone K30 20 g/kg, sodium lauryl sulfate 5.0 g/kg, and anhydrous citric acid 5.0 g/kg. The formulation is dry-blended because wet granulation will prematurely bind the API into slow-dissolving agglomerates in hard water with calcium carbonate equivalents above 200 mg/L. Downstream processing passes the powder through a cone mill fitted with an 800 µm screen to eliminate lumps, then mixes it in a 1,000 L ribbon blender at 15 rpm for 10 min after the API is pre-blended with an equal portion of lactose. Bulk density is controlled at 0.60–0.75 g/mL by USP Chapter 616. The powder must disperse in 25°C water within 120 s without forming a surface film. Dissolution performance is checked by adding 5 g powder to 1 L water at 25°C with paddle stirring at 150 rpm; no particulate residue on a 74 µm screen after 120 s is the in-process release criterion. Production-scale failures occur when the blend is overmixed beyond 20 min; the added shear increases electrostatic charge on the micronized API and creates wall adhesion in stainless steel equipment. Compliance anchors include Ph. Eur. 5.1.4 for microbiological quality of non-sterile oral powders, VICH GL18 for residual solvents, and national veterinary prescription controls. Moisture content is kept at ≤2.0% by Karl Fischer titration. Terminal finished product types include 100 g, 500 g, 1 kg aluminium-foil laminate sachets and 25 kg bulk drums for drinking-water administration in broilers, layers, and turkeys.

Feed Premix Dilution and Carryover Control in High-Throughput Broiler Lines

Medicated premix manufacture from Cufanchu Powder is governed by feed law more than by human pharmaceutical GMP. A 10.0% w/w premix is produced by weighing 10.0 kg API and blending it stepwise with a carrier system of corn cob meal 85.0% w/w and mineral oil 1.0% w/w to 100 kg total. Mineral oil reduces dusting and electrostatic segregation but increases wall adhesion if added above 2.0% w/w. In finished feed, an inclusion rate of 1.0 kg premix per 1,000 kg feed yields 100 mg/kg active ingredient. Production equipment is a horizontal ribbon mixer with working capacity 500 kg; the API is first pre-blended with 5.0 kg carrier in a 50 L drum blender for 3 min, then transferred to the ribbon mixer containing 50% of total carrier and mixed for 8 min. Remaining carrier is added and mixed for 10 min. Sampling uses a 10-point thief probe; if the relative standard deviation of active content exceeds 5.0%, mixing is extended in 2-min increments and re-sampled. After batch discharge, residual API in the mixer and downstream conveying lines must remain below 0.1% of the next batch active concentration; a wash with coarse rice hulls reduces cross-contamination before line clearance. Cleaning validation limits are calculated from the permitted daily exposure of the most sensitive target species divided by the next product daily intake; if active residue on equipment exceeds 0.1% of the next batch concentration, swab sampling of mixer walls, ribbon shaft, and discharge hopper is performed. Mixer dead zones near the ribbon shaft ends can retain 0.3–0.5 kg material when the hopper wall angle is below 60°. Compliance anchors are EU Regulation (EC) No 1831/2003, FAMI-QS 6.0, ISO 22000:2018, and national veterinary premix registration. Finished products are 20 kg and 25 kg multilayer paper bags with polyethylene liner, delivered to feed mills for broiler, pig, and layer rations.

When Oral Drench Solutions Require pH Buffering to Prevent Alkaline Precipitation

An oral solution containing Cufanchu API at 5.0% w/v is prepared for drench administration in cattle and sheep. The formula uses propylene glycol 20.0% v/v, liquid sorbitol 70% 10.0% w/v, sodium metabisulfite 0.1% w/v as antioxidant, and purified water q.s. to 100 mL. The pH is adjusted to 4.0–5.0; above 6.5, precipitation risk increases in hard water with calcium carbonate equivalents above 200 mg/L. Published alkalinity tolerance data for this specific Cufanchu oral solution configuration are limited; the pH adjustment is derived from general veterinary drench formulation stability practice. Mixing is conducted in a 1,000 L stainless steel vessel under nitrogen sparging at 0.2 L/min to limit oxidation. Viscosity at 20°C is controlled at 50–150 mPa·s using a Brookfield LV viscometer spindle 1 at 60 rpm. The solution is clarified through a 20 µm polypropylene filter and filled into amber HDPE containers in a Class D cleanroom. Compliance anchors include Ph. Eur. 5.1.4 for microbiological quality of non-sterile liquid dosage forms, VICH GL11 for stability testing, and Ph. Eur. 2.9.7 for clarity and degree of opalescence. Terminal finished types include 500 mL, 1 L, 5 L drench bottles and 20 L drum stock.

Granulation of Cufanchu Powder into free-flowing oral granules for swine top-dress application is performed by wet granulation with a binder solution rather than by dry blending, because granule density and dust control are the primary acceptance criteria. A batch formula for 5.0% w/w granules consists of API 50 g/kg, microcrystalline cellulose 200 g/kg, maize starch 700 g/kg, povidone K30 30 g/kg, and purified water q.s. as granulation fluid. Granulation is performed in a high-shear mixer-granulator with impeller speed 300 rpm and chopper speed 1,500 rpm for 4 min, followed by extrusion through a 1.0 mm screen and spheronization at 800 rpm for 2 min. Drying is performed in a fluid-bed dryer at inlet air 55–65°C until loss-on-drying is ≤2.0%. The granule fraction between 0.5 mm and 1.25 mm is retained; fines below 0.5 mm are recycled at not more than 20% of the batch weight. Higher fines recycle reduces granule strength and increases dust during filling. Compliance anchors include Ph. Eur. 2.9.40 for content uniformity, Ph. Eur. 2.9.1 for disintegration where applicable, USP Chapter 1112 for water activity control at ≤0.60, and VICH GL18 for residual solvents. Finished types include 1 kg and 5 kg high-density polyethylene jars of oral granules for piglets and grower pigs.